Hypothermic oxygenated perfusion (HOPE) is an emerging technique for donor heart preservation that is currently being studied in multiple clinical trials with promising results. When compared to HOPE for other organs, cardiac protocols involve red blood cell (RBC) supplementation, despite absence of comparative evidence for its benefits. In this perspective paper, we discuss the pros and cons of the addition of RBCs during cardiac HOPE. Although the current clinical results with RBC supplementation during HOPE seem promising, potential downsides of RBC supplementation cannot be ruled out. The impact of supplemented RBCs during cardiac HOPE requires further investigation to improve HOPE protocols, to optimize heart preservation using this promising technology.

中文翻译：

---

关于心脏低温含氧灌注期间红细胞附加值的观点。


低温氧合灌注 （HOPE） 是一种新兴的供体心脏保存技术，目前正在多项临床试验中进行研究，并取得了可喜的结果。与其他器官的 HOPE 相比，心脏方案涉及红细胞 （RBC） 补充，尽管缺乏其益处的比较证据。在这篇透视论文中，我们讨论了在心脏 HOPE 期间添加红细胞的利弊。尽管目前在 HOPE 期间补充红细胞的临床结果似乎很有希望，但不能排除补充红细胞的潜在缺点。在心脏 HOPE 期间补充红细胞的影响需要进一步研究以改进 HOPE 方案，以使用这项有前途的技术优化心脏保存。